PF-Atlas › Clinical Trials › NCT06241560

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

BI 1015550 · Phase 2

Registry ID
NCT06241560
Phase
Phase 2
Status
Completed
Drug / intervention
BI 1015550
Sponsor
Boehringer Ingelheim
Start
2026-03-05
Enrollment
20
Locations
3

About this trial

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is important to understand how different medicines influence one another. Participants take one dose of BI 1015550 as a tablet. Participants then take one tablet of pirfenidone 3 times a day for one week. The dose is then increased to 2 tablets 3 times a day for the second week. In the third week the dose is increased further to 3 tablets 3 times a day. Participants then take another dose of BI 1015550 as a tablet. Participants are in the study for a little over 1 month. During this

View NCT06241560 on ClinicalTrials.gov →

Medical disclaimer. This page summarizes public trial data for NCT06241560 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.